Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1097-1103
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1097
Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: Where we are now
Caecilia H C Sukowati, Sri Jayanti, Turyadi Turyadi, David H Muljono, Claudio Tiribelli
Caecilia H C Sukowati, Sri Jayanti, Turyadi Turyadi, Eijkman Research Center for Molecular Biology, Research Organization for Health, National Research and Innovation Agency of Indonesia, Jakarta 10340, Indonesia
Caecilia H C Sukowati, Claudio Tiribelli, Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, Trieste 34149, Italy
David H Muljono, Faculty of Medicine, Hasanuddin University, Makassar 90245, South Sulawesi, Indonesia
David H Muljono, Faculty of Medicine and Health, University of Sydney, Sydney 2050, Australia
Author contributions: Sukowati CHC, Jayanti S, Turyadi T, Muljono DH, and Tiribelli C contributed to this paper; Sukowati CHC designed the overall concept and outline of the manuscript; Sukowati C, Jayanti S, and Turyadi T contributed to the writing, editing the manuscript, and review of literature; Sukowati CHC, Muljono DH, and Tiribelli C contributed to the discussion and the editing of the manuscript.
Supported by Rumah Program 2024 of Research Organization for Health, National Research and Innovation Agency of Indonesia; 2023 Grant of The Fondazione Veronesi, Milan, Italy (Caecilia H C Sukowati); and 2023/2024 Postdoctoral Fellowship of The Manajemen Talenta, Badan Riset dan Inovasi Nasional, Indonesia (Sri Jayanti).
Conflict-of-interest statement: All authors declare no conflict-of-interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Caecilia H C Sukowati, PhD, Senior Scientist, Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, AREA Science Park Campus Basovizza, SS14, km 163.5, Trieste 34149, Italy. caecilia.sukowati@fegato.it
Received: January 4, 2024
Peer-review started: January 4, 2024
First decision: January 17, 2024
Revised: January 30, 2024
Accepted: March 6, 2024
Article in press: March 6, 2024
Published online: April 15, 2024
Processing time: 97 Days and 17.1 Hours
Core Tip

Core Tip: This article discusses recent updates on the classification of hepatitis B virus (HBV) based on its genetic diversity (genotype) and its relationship with current data in HBV pathogenicity, hepatocellular carcinoma (HCC), and HCC treatment.